Skip to content

Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy

The Effect of a Systemic Non-selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00452283
Enrollment
23
Registered
2007-03-27
Start date
2007-03-31
Completion date
2011-05-31
Last updated
2013-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Pulmonary Hypertension

Brief summary

There is growing evidence that a cause of glaucoma is linked to circulatory problems and poor auto-regulation of blood flow to the optic nerve. Pulmonary hypertension (PH)is a disease characterized by low oxygen levels in the blood and altered blood circulation. The decrease in oxygen delivery to the optic nerve could lead to the loss of nerve fiber layer(NFL)in the retina and the resulting visual field compromise. This situation is characteristic of glaucoma. The ability to identify NFL thinning early could lead to earlier diagnosis of glaucoma and more effective treatment to limit dysfunction from visual field loss. We hypothesize that the rate of structural damage to the NFL, a feature of glaucoma, is higher in patients with PH than expected in healthy populations lacking this disease.

Interventions

None listed

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diagnosed with pulmonary hypertension * between the ages of 18 and 80 years * ability to undergo the various ocular exams.

Exclusion criteria

* patients with other diseases that could affect the nerve fiber layer * special populations; ie children, pregnancy, lactating females, prisoners

Design outcomes

Primary

MeasureTime frame
Occurence of nerve fiber layer abnormalitiesSingle Exam

Secondary

MeasureTime frame
Optic Nerve Head StructureSingle Exam

Other

MeasureTime frame
Visual Field DefectsSingle Exam
Retinal Blood Flow ChangesSingle Exam

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026